UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2026

Vivani Medical, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-36747**	**02-0692322**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

1350 S. Loop Road **Alameda, California**	**94502**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (415) 506-8462

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	VANI	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. **Regulation FD Disclosure.**

Vivani Medical, Inc. (the "Company" or "Vivani") made a presentation at the Emerging Growth Conference in New York on Wednesday, July 15, 2026 at 4:10 p.m. Eastern Time. A copy of a slide presentation that Dr. Adam Mendelsohn, Vivani's Chief Executive Officer, used during the conference, which includes an update that the expected date for the Company's first dosing of SLIM-1 is expected to take place in August 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The slide presentation speaks only as of the date of this Current Report on Form 8-K. While Vivani may elect to update the slide presentation in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Vivani specifically disclaims any obligation to do so.

The information contained in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information contained in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	**Description**
99.1	Vivani Medical, Inc. slide presentation dated July 15, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIVANI MEDICAL, INC.

Date: July 16, 2026

By: /s/ Donald Dwyer
Name: Donald Dwyer
Title: Chief Business Officer

Disclaimers

The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans" or "planned," "strategy," "goal," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Vivani Medical, Inc. ("Vivani", the "Company", "we" or "us") expects or anticipates will occur in the future, such as stated objectives or goals, our products and their therapeutic potential and planned development, the indications that we intend to target, our technology, our business and strategy, milestones, addressable markets, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this presentation on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors. These risks and uncertainties include, but are not limited to, that we may fail to commence our planned future clinical trials for products under development; conduct any pre-clinical activities of our other products; our products may not demonstrate safety or efficacy in clinical trials; we may fail to secure marketing approvals for our products; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our products may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks and uncertainties are described in our Annual Report on Form 10-K filed on March 26, 2026, our Quarterly Report on Form 10-Q filed on May 13, 2026, and our subsequent filings with the U.S. Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and the Company's own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. All of our therapies are still investigational and have not been approved by any regulatory authority for any use.

Vivani

The obesity market is evolving

What will it take to be successful in the future?

In addition to the currently FDA-approved products on the market, there are over 50 in clinical development. All of these are injectables or orals. Vivani's implant uniquely combines infrequent (e.g., once- or twice-yearly) administration with the ability to stop treatment quickly, if necessary.

A differentiated route of administration presents opportunities to access untapped segments of this market, transition experienced patients to a longer-acting option, and help patients struggling with adherence to have access to a guaranteed-adherence option.

FDA-approved GLP-1 injectables

3

novo nordisk® Lilly

FDA-approved GLP-1 orals

2

novo nordisk® Lilly

Clinical-stage injectables or orals for obesity

>50

novo nordisk Lilly AMGEN VIKING Pfizer MERCK innovent altimmune kailera Roche septerna Structure MindRank AstraZeneca Boehringer Ingelheim

Clinical-stage subdermal implant

1

Vivani

Vivani

Vivani's differentiated product candidates are designed to address unmet needs and expand the market

Market Challenges

- **Suboptimal outcomes**
  Poor medication adherence (<50%) leads to loss of efficacy and rapid weight rebound
- **Tolerability issues**
  Dose fluctuations and pharmacokinetic (PK) variability provoke side effects
- **Underserved & unaddressed populations**
  Current options not ideal for hard-to-reach, difficult-to-manage, discretion- or convenience-seeking patients

The NanoPortal™ Promise

- **Convenient, guaranteed adherence**
  Designed to maintains therapeutic effect and deliver medical and pharmacoeconomic outcomes
- **Stable delivery**
  Expected to reduce side effects associated with fluctuating drug plasma levels
- **Differentiated modality**
  Infrequent, in-office administration by primary care professionals solves logistical impasse for underserved populations

Vivani

Vivani Medical, Inc.

A clinical stage innovator uniquely positioned to address the future challenges and opportunities of an evolving obesity market

Our focus: Enhance patient outcomes and GLP-1 market uptake in chronic diseases via unique route of administration, improved patient adherence, tolerability, and convenience

Technology: NanoPortal ultra long-acting, miniature drug implants designed to enable very infrequent dosing, including every 6 months, 12 months, or longer

Lead program: NPM-139 is a miniature, subdermal, semaglutide implant for chronic weight management in obese and overweight individuals

Clinical success: LIBERATE-1 first-in-human study achieved the primary objectives including positive safety, tolerability and device performance

Platform Proof of Concept: Preclinical weight loss of ~20% sustained for a full year

Nasdaq: VANI

- ✓ Cash runway expected to fund current operating plan, including completion of key milestones, through 1H2027
- ✓ NPM-139 clinical program initiation in mid-2026
- ✓ Highly specialized & proprietary manufacturing operations in Alameda, CA

GLP-1 market expected to grow to $190B by 2035*

*Morgan Stanley Research published in April 2026 estimates the global GLP-1 market could reach approximately $190 billion by 2035 across obesity and diabetes, with an obesity-only TAM of approximately $150 billion. Current eligible-patient penetration in the U.S. is estimated at approximately 6%; a bull-case projection is approximately $240 billion. https://www.morganstanley.com/insights/articles/glp1-weight-loss-market-may-double-190-billion-2035

Vivani

Company pipeline utilizing NanoPortal platform

If approved, Vivani products would provide a differentiated ultra long-acting option for patients



*This includes a number of next-generation incretins (i.e., more potent and/or multi-agonists), including retatrutide. Early retatrutide implant PK data is featured later in this presentation.
**In partnership with Okava Pharmaceuticals, Inc.

Vivani

Good things come in small packages

01 GLP-1 implant & applicator

- ✓ Simple administration, in-office procedure to insert the implant comfortably under the skin for twice-yearly dosing designed to produce Wegovy®-level efficacy

02 NanoPortal device elements

- ✓ Designed to assure adherence
- ✓ Long-term delivery
- ✓ Stable and tunable release profile



03 NanoPortal technology

- ✓ Nanotube pore size is precisely tunable to achieve near-constant release profiles



Vivani

Vivani Lead Program: NPM-139

SLIM™: Semaglutide ultra Long-acting IMplant in obesity

Vivani

July 7, 2026: Vivani announces the signing of a new agreement with Novo Nordisk

The agreement at a glance

- **Agreement enables Novo Nordisk to evaluate NPM-139, Vivani's semaglutide drug implant for chronic weight management**
- **There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology, associated with this agreement**

"The new agreement announced today supporting our semaglutide implant program in chronic weight management **demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application**. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM 139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary."

- Adam Mendelsohn, PhD, CEO of Vivani

Vivani

Persistence and adherence are critical to securing desired long-term health outcomes

Persistence data comparing obesity therapies suggest room for improvement across the board, including for semaglutide. The unmet need is significant.

- The opportunity for an additional 60% improvement in persistence for semaglutide is remarkable and could translate to improved patient outcomes
- Semaglutide implant is designed to guarantee adherence during the entire once- or twice-yearly dosing interval



** Implant not included in this Large Retrospective Cohort Study, included for illustrative purposes only; assumes full replacement at 6 months

Vivani

* Published in Obesity, December 8, 2023

Semaglutide discontinuation leads to rapid hunger-induced weight rebound

Sudden GLP-1 withdrawal produces immediate rebound hunger, leading to rapid weight regain mediated by greater food consumption



STEP 1 Extension: Semaglutide Withdrawal
From Novo Nordisk Wegovy® Clinical Program

Vivani

NPM-139 provides steady preclinical pharmacokinetics

***In vivo* pharmacokinetics of NPM-139 configurations in Sprague-Dawley rats.** Values are mean ± SE.

*****n=5 through day 28; two implants removed at Day 28 for characterization, n=3 thereafter.



Vivani

NPM-139 clinical and regulatory development: Near-term plan builds on recent wins

Milestone	Status
Announced LIBERATE-1 completed and met the primary study objectives; reported positive weight loss in preclinical study with semaglutide	August 2025
Disclosed proposed clinical program including Phase 1 PK and Phase 2 dose-ranging weight maintenance studies	September 2025
Secured approval from HREC in Australia to initiate SLIM-1™	June 2026
First Dosing for SLIM-1™	August 2026 (projected)

NPM-139 Phase 1 study design: SLIM-1™

Primary Objectives
Safety/tolerability assessment and pharmacokinetic characterization

Key Inclusion/Exclusion Criteria
18-55 years old; overweight or obese (BMI 27-40)
Otherwise healthy (no T2D)



T2D = Type 2 Diabetes; EOT = End of Treatment

Proposed NPM-139 Phase 2 study design: SLIM-2™



*unblinded

NanoPortal retatrutide implant provides steady preclinical pharmacokinetics in ongoing study

***In vivo* pharmacokinetics of prototype NanoPortal retatrutide implant in Sprague-Dawley rats in an ongoing study.** Values are mean ± SE.



Guaranteed adherence. Improved outcomes.

- **Only GLP-1 implant in development for obesity and chronic weight management**
- **Convenient once- or twice-yearly dosing expected to address primary GLP-1 market challenges**
- **Unique modality designed to reach underserved & unaddressed populations key to market expansion**

Vivani

Vivani™
Nasdaq: VANI

Thank You

Company Contact:
Donald Dwyer, Chief Business Officer
info@vivani.com

Investor Relations Contact:
Jami Taylor, Investor Relations Advisor
investors@vivani.com

www.vivani.com